Long non-coding RNA expression profiles in peripheral blood mononuclear cells of patients with coronary artery disease

Abstract Background: Plasmacytoma variant translocation 1 (PVT1) is a newly discovered long non-coding RNA (lncRNA), and it has not been previously studied in the inflammatory responses of peripheral blood mononuclear cells (PBMCs) of patients with coronary artery disease (CAD). Methods: This cross-sectional study was conducted in 15 CAD patients and 15 non-CAD (NCAD) individuals. PVT1 expression in PBMCs of the participants was measured, using real-time PCR. Interleukin (IL)-10, IL-22 and MMP-9 in the plasma and supernatant of the cultured PBMCs in the presence or absence of lipopolysaccharide (LPS) was assessed, using flowcytometry and ELISA.Results: An increased expression of PVT1 was observed in untreated PBMCs of CAD patients compared to the NCAD group. There was a significant up-regulation of PVT1 after LPS treatment in PBMCs of both groups. Plasma matrix metalloproteinase-9 (MMP-9) levels were found to be higher in CAD patients compared to the controls. The level of IL-10 and IL-22 production from the non-treated PBMCs of CAD was significantly lower compared to the NCAD group. In the total examined population, PVT1 expression was negatively correlated with IL-10 secretion. The results also showed a significant negative correlation between PVT1 expression and IL-10 produced by untreated cells. Conclusions: PVT1 expression is increased in PBMCs of CAD patients and this increased expression could be associated with decreased IL-10 production from PBMCs of these patients.

Download Full-text

Long non coding RNA expression profile in Peripheral Blood Mononuclear Cells from Multiple Sclerosis patients: potential biomarkers of disease susceptibility and progression

10.26226/morressier.59a3edabd462b8028d895064 ◽

2017 ◽

Author(s):

Emanuela Oldoni

Keyword(s):

Multiple Sclerosis ◽

Disease Susceptibility ◽

Mononuclear Cells ◽

Rna Expression ◽

Peripheral Blood Mononuclear ◽

Non Coding Rna ◽

Blood Mononuclear Cells ◽

Multiple Sclerosis Patients ◽

Long Non Coding Rna ◽

Potential Biomarkers

Download Full-text

Abstract 580: Lutein Reduces Inflammation in Patients With Coronary Artery Disease by Suppressing Cytokine and Matrix Metalloproteinase-9 Secretion From Peripheral Blood Mononuclear Cells

Arteriosclerosis Thrombosis and Vascular Biology ◽

10.1161/atvb.36.suppl_1.580 ◽

2016 ◽

Vol 36 (suppl_1) ◽

Author(s):

Rosanna W Chung ◽

Per Leanderson ◽

Anna K Lundberg ◽

Lena Jonasson

Keyword(s):

Coronary Artery Disease ◽

Coronary Artery ◽

Mononuclear Cells ◽

Peripheral Blood Mononuclear ◽

Blood Mononuclear Cells ◽

Anti Inflammatory ◽

Artery Disease ◽

Stable Cad ◽

Metalloproteinase 9

Introduction: Low plasma carotenoid levels are associated with increased cardiovascular risk factors. Carotenoids are anti-oxidants with potential anti-inflammatory properties. In this study, we measured different types of carotenoid in plasma and assessed their relationship with interleukin-6 (IL-6) in patients with acute coronary syndrome (ACS) or stable coronary artery disease (CAD). A sub-cohort was followed for 12 months. Moreover, we assessed the anti-inflammatory effects of lutein in peripheral blood mononuclear cells (PBMC) collected from CAD patients. Methods: We included 48 ACS and 109 stable CAD patients. Circulating levels of lutein+zeaxanthin, β-cryptoxanthin, lycopene, α- and β-carotene, and IL-6 were measured. Lutein and zeaxanthin are isomers and as such measured together. Lutein, however, is the major form of the isomers. PBMC were treated with lutein (1μM, 5μM and 25μM) for 24hr followed by 24hr incubation with or without LPS. Cytokines and matrix metalloproteinase-9 (MMP-9) in cell media were measured. Results: Levels of lutein+zeaxanthin and lycopene were inversely correlated to IL-6 in the whole cohort, p <0.001 and p <0.05, respectively. In stable CAD patients, only lutein+zeaxanthin were correlated to IL-6 ( p <0.001). In the sub-cohort (n=33), changes in IL-6 were inversely correlated to changes in lutein+zeaxanthin at the 3 rd month ( p <0.01) and 12 th month ( p <0.05). Changes in IL-6 were also inversely correlated to changes in lycopene levels at 12 th month ( p <0.05). Other carotenoids did not correlate to IL-6 in plasma. In vitro , spontaneous and LPS-induced secretion of cytokines (IL-6, IL-1β and TNF-α) and MMP-9 from PBMC were dose-dependently and significantly reduced by lutein. Conclusions: The clinical findings indicated that lutein+zeaxanthin might play a role in resolution of inflammation in CAD patients. In vitro , we were able to confirm that lutein exerted anti-inflammatory effects by suppressing secretion of inflammatory cytokines and MMP-9 from PBMC.

Download Full-text